Overview
Central retinal vein occlusion (CRVO) is a condition where the main vein that drains blood from the retina (the light-sensitive tissue at the back of the eye) becomes blocked. When this vein is blocked, blood and fluid back up into the retina, causing swelling, bleeding, and damage to the delicate tissue needed for vision. This leads to sudden, painless vision loss in the affected eye, which can range from mild blurriness to severe loss of sight. CRVO is sometimes called a "retinal stroke" because, like a stroke in the brain, it involves a blockage of blood flow. The condition is more common in older adults and in people who have high blood pressure, diabetes, glaucoma, or blood clotting disorders. It can affect one or both eyes, though one eye is more typical. Treatment focuses on managing complications and preserving as much vision as possible. Anti-VEGF injections (medications injected into the eye) are the main treatment and help reduce swelling in the retina. Steroid implants may also be used. Laser treatment was once the standard but is now used less often. Managing underlying conditions like high blood pressure and diabetes is also a critical part of care. While some people recover good vision, others may experience lasting vision problems, and complications like abnormal blood vessel growth (neovascularization) can lead to further issues if not treated promptly.
Also known as:
Key symptoms:
Sudden painless vision loss in one eyeBlurry or distorted visionDark spots or floaters in visionLoss of central visionDifficulty reading or recognizing facesColors appearing washed out or different between eyesA dark or missing area in your field of visionGradual worsening of vision over days to weeksEye pain or pressure (in severe cases with complications)Redness of the eye (in advanced cases)
Clinical phenotype terms (16)— hover any for plain English
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsJakkrit Juhong — NA
Sam Chun Dang Pharm. Co. Ltd. — PHASE2
Harrow Inc — PHASE4
Inje University — NA
Bayer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — NA
Annexin Pharmaceuticals AB — PHASE2
MediBeacon — EARLY_PHASE1
SciNeuro — PHASE2
Tanta University — EARLY_PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableEylea
indicated for the treatment of patients with Macular Edema Following Retinal Vein Occlusion (RVO)
Ozurdex
The treatment of macular edema following branch retinal vein occlusion (BRVO)
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Central retinal vein occlusion.
Community
No community posts yet. Be the first to share your experience with Central retinal vein occlusion.
Start the conversation →Latest news about Central retinal vein occlusion
Disease timeline:
New recruiting trial: Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Effect of Video Viewing on Intravitreal Injection Experience
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
A new clinical trial is recruiting patients for Central retinal vein occlusion
New recruiting trial: Combination of Ranibizumab and Targeted Laser Photocoagulation
A new clinical trial is recruiting patients for Central retinal vein occlusion
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Is my CRVO the non-ischemic or ischemic type, and what does that mean for my vision?,How often will I need eye injections, and how long will treatment continue?,What underlying health conditions should I be tested for or manage more aggressively?,What are the warning signs that my condition is getting worse or developing complications?,Should I be tested for blood clotting disorders, especially if I am younger?,What can I do to protect the vision in my other eye?,Are there low-vision resources or rehabilitation services that could help me?
Common questions about Central retinal vein occlusion
What is Central retinal vein occlusion?
Central retinal vein occlusion (CRVO) is a condition where the main vein that drains blood from the retina (the light-sensitive tissue at the back of the eye) becomes blocked. When this vein is blocked, blood and fluid back up into the retina, causing swelling, bleeding, and damage to the delicate tissue needed for vision. This leads to sudden, painless vision loss in the affected eye, which can range from mild blurriness to severe loss of sight. CRVO is sometimes called a "retinal stroke" because, like a stroke in the brain, it involves a blockage of blood flow. The condition is more common
How is Central retinal vein occlusion inherited?
Central retinal vein occlusion follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Central retinal vein occlusion typically begin?
Typical onset of Central retinal vein occlusion is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Central retinal vein occlusion?
Yes — 20 recruiting clinical trials are currently listed for Central retinal vein occlusion on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Central retinal vein occlusion?
25 specialists and care centers treating Central retinal vein occlusion are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Central retinal vein occlusion?
2 patient support programs are currently tracked on UniteRare for Central retinal vein occlusion. See the treatments and support programs sections for copay assistance, eligibility, and contact details.